MHRA
Regulating Medicines and Medical Devices

MHRA
151 Buckingham Palace Road
London SW1W 9SZ
United Kingdom

mhra.gov.uk

Ms N Boota
UNIVERSITY OF WARWICK
WARWICK CLINICAL TRIALS UNIT, WARWICK MEDICAL SCHOOL
GIBBET HILL ROAD
COVENTRY
CV4 7AL
UNITED KINGDOM

18/09/2017

Dear Ms N Boota

THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031

Our reference:	16719/0231/001-0001
Eudract Number:	2017-001785-14
Product:	Landiolol hydrochloride 300 mg lyophilised powder
Protocol number:	STRESS-L

NOTICE OF ACCEPTANCE

I am writing to inform you that the Licensing Authority accepts your request for a clinical trial authorisation (CTA), received on 23/08/2017.

The authorisation is effective from the date of this letter although your trial may be suspended or terminated at any time by the Licensing Authority in accordance with regulation 31. You must notify the Licensing Authority within 90 days of the trial ending.

Finally, you are reminded that a favourable opinion from the Ethics Committee is also required before this trial can proceed.

Yours sincerely,

Clinical Trials Unit
MHRA